176 related articles for article (PubMed ID: 33477150)
1. Implications of Hidradenitis Suppurativa Phenotypes in Cardiovascular Risk and Treatment Decisions: A Retrospective Cohort Study.
Cuenca-Barrales C; Montero-Vilchez T; Salvador-Rodríguez L; Sánchez-Díaz M; Arias-Santiago S; Molina-Leyva A
Dermatology; 2021; 237(5):727-732. PubMed ID: 33477150
[TBL] [Abstract][Full Text] [Related]
2. Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern.
Pinter A; Sarlak M; Zeiner KN; Malisiewicz B; Kaufmann R; Romanelli M; Koenig A; Chiricozzi A
Dermatology; 2021; 237(5):759-768. PubMed ID: 33326954
[TBL] [Abstract][Full Text] [Related]
3. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
[TBL] [Abstract][Full Text] [Related]
4. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
5. Hidradenitis suppurativa in Crohn's disease during adalimumab therapy: a paradox?
Martina E; Campanati A; Giuliodori K; Offidani A
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):21-23. PubMed ID: 28352932
[TBL] [Abstract][Full Text] [Related]
6. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
Clin Exp Dermatol; 2021 Mar; 46(2):306-313. PubMed ID: 32931599
[TBL] [Abstract][Full Text] [Related]
7. Hidradenitis suppurativa: Current and emerging treatments.
Goldburg SR; Strober BE; Payette MJ
J Am Acad Dermatol; 2020 May; 82(5):1061-1082. PubMed ID: 31604100
[TBL] [Abstract][Full Text] [Related]
8. Steatocystoma multiplex suppurativa associated with hidradenitis suppurativa successfully treated with adalimumab.
Atzori L; Zanniello R; Pilloni L; Rongioletti F
J Eur Acad Dermatol Venereol; 2019 Oct; 33 Suppl 6():42-44. PubMed ID: 31535759
[TBL] [Abstract][Full Text] [Related]
9. British Association of Dermatologists National Clinical Audit on the Management of Hidradenitis Suppurativa in the UK.
Hasan SB; Smith SP; Brain A; Mohd Mustapa MF; Cheung ST; Ingram JR; de Berker DAR
Clin Exp Dermatol; 2021 Aug; 46(6):1023-1027. PubMed ID: 33577133
[TBL] [Abstract][Full Text] [Related]
10. Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.
Kimball AB; Ganguli A; Fleischer A
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2254-2256. PubMed ID: 29959796
[TBL] [Abstract][Full Text] [Related]
11. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS).
Hessam S; Sand M; Gambichler T; Bechara FG
J Am Acad Dermatol; 2015 Dec; 73(6):998-1005. PubMed ID: 26410359
[TBL] [Abstract][Full Text] [Related]
12. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
13. Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts.
Condamina M; Penso L; Tran VT; Hotz C; Guillem P; Villani AP; Perrot P; Bru MF; Jacquet E; Nassif A; Bachelez H; Wolkenstein P; Beylot-Barry M; Richard MA; Ravaud P; Viguier M; Sbidian E
Dermatology; 2021; 237(5):748-758. PubMed ID: 33503635
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
Marzano AV; Genovese G; Casazza G; Moltrasio C; Dapavo P; Micali G; Sirna R; Gisondi P; Patrizi A; Dini V; Bianchini D; Bianchi L; Fania L; Prignano F; Offidani A; Atzori L; Bettoli V; Cannavò SP; Venturini M; Bongiorno MR; Costanzo A; Fabbrocini G; Peris K
Br J Dermatol; 2021 Jan; 184(1):133-140. PubMed ID: 32119111
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with hidradenitis suppurativa.
Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
[TBL] [Abstract][Full Text] [Related]
16. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
[TBL] [Abstract][Full Text] [Related]
17. Interventions for Hidradenitis Suppurativa: Updated Summary of an Original Cochrane Review.
Ingram JR
JAMA Dermatol; 2017 May; 153(5):458-459. PubMed ID: 28355440
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.
Diamantova D; Lomickova I; Cetkovska P
Acta Dermatovenerol Croat; 2014; 22(4):291-3. PubMed ID: 25580790
[TBL] [Abstract][Full Text] [Related]
20. New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes.
van der Zee HH; Jemec GB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S23-6. PubMed ID: 26470610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
